Patent NZ-516003-A (NZ)
Title: Inhibitors of aspartyl protease
Inventor: HALE MICHAEL ROBIN
IPC: A61K/
Filed: 2000-06-08
Abstract: A compound or pharmaceutically acceptable salts thereof has the formula (I) wherein: A is H, Ht, -R1-Ht, optionally substituted -R1-alkyl or -R1- alkenyl, or R7; each R1 is independently -C(O)-, -S(O)2-, -C(O)-C(O)-, -O- S(O)2, -NR2-, -O-C(O)-, -NR2-C(O)-C(O)-, -NR2-S(O)2- or - NR2-C(O)- and each Ht is independently optionally substituted cycloalkyl, cycloalkenyl, aryl, or a 5-7 membered optionally saturated heterocycle, containing one or more heteroatoms of N, N(R2), O, S or S(O)n and the aryl or heterocycle can be optionally fused to Q; G, when present, is H, R7 or alkyl, or, when G is alkyl, G and R7 are bound to one another either directly or through a C1-C3 linker to form a heterocyclic ring, or when G is not present then the nitrogen to which G is attached is bound directly to the R7 group in -OR7 with the concomitant displacement of one -ZM group from R7 when R7 is -[CH2-O]x- Y(=X)(ZM)Z(M)x; n is 1 or 2 and x is 0 or 1; D is Q substituted alkyl or alkenyl, which can be also optionally substituted, or Q is cycloalkyl or cycloalkenyl which is substituted with or fused to Q; each Q is independently an optionally saturated optionally substituted 3-7 membered carbocyclic ring system or a 5-7 membered heterocyclic ring containing one or more heteroatoms O, N, S, S(O)n or N(R2) and Q contain one substituent of -OR2, -OR8, -SR8, -S-arylalkyl, O-arylalkyl,- N(R2)R8 or N(R2)-arylalkyl provided that when D is alkyl substituted with Q and Q is phenyl or naphthyl Q is not substituted with OH, -O-unsubstituted alkyl, -NH2, -SH, -S- unsubstituted alkyl or haloalkyl; D' is optionally substituted alkyl, alkoxy, alkenyl, alkenyloxy, alkynyl, or alkynyloxy and E is Ht, Ht-Ht, Ht fused with Ht, -N(R2)(R3), OR3 or optionally substituted alkyl, alkenyl or optionally saturated carbocycle; each R7 is independently hydrogen, -[CH2-O]x-Y(=X)(ZM)Z(M)x or -{CH2-O]x-C(=O)-(R9)xM'; each M is independently H, Li, Na, K, Mg, Ca, Ba, -N(R2)4, optionally substituted alkyl or alkenyl, or -R6 and 1 to 4 CH2 radicals of the alkyl or alkenyl group, other than the- CH2 that is bound to Z is optionally replaced by a heteroatom group O, S, S(O), S(O)2, or N(R2) and M' is H, optionally substituted alkyl or alkenyl or -R6 and 1 to 4 CH2 radicals of the alkyl or alkenyl group, other than the- CH2 that is bound to Z is optionally replaced by a heteroatom group O, S, S(O), S(O)2, or N(R2); Z is O, S, N(R2)2 or when M is not present, Z is H and Y is P or S and when Y is S, Z is not S; X is O or S and R2, R8 and R6 are as defined in the specification. The compounds are useful for treating a patient infected with a virus that depends upon an aspartyl protease for an obligatory event in its life cycle and can be used to treat a patient infected with HIV-I or HIV-II, AIDS, AIDS related complex (ARC), progressive generalized lymphadenopathy (PGL), Kapos's sarcoma, thrombocytopenic purpura, anti-HIV antibody-positive conditions, HIV-positive conditions AIDS- related neurological conditions such as AIDS dementia complex, multiple sclerosis or tropical paraperesis.